A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using ...

A single infusion of a gene-editing therapy has all but shut off the disabling, sometimes life-threatening swelling attacks ...

Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose ...

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is an advanced technology developed in 2012 that can be used to edit genes. It can be used to find specific DNA sequences inside ...

CRISPR's expanding pipeline could unlock significantly more value by 2031.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. 22 May 2018, Germany, Berlin: A researcher performs a CRISPR/Cas9 process at the ...

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive ...

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval comes ...

NEW ORLEANS, LA—An investigational CRISPR-Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3), which has a role in regulating lipid metabolism, appears to safely lower levels ...

Phase 3 HAELO data showed an 87% reduction in monthly attack rates with Ionvoguran ziclumeran, with a PDUFA target date of March 10, 2027.

Add Yahoo as a preferred source to see more of our stories on Google. Doctors used personal gene therapy to treat an infant with a deadly genetic disease in a medical first. KJ Muldoon was born in ...

(NewsNation) — Doctors used personal gene therapy to treat an infant with a deadly genetic disease in a medical first. KJ Muldoon was born in August of 2024, and DNA sequencing revealed he had ...